Published in Ann Neurol on October 01, 1999
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia (2007) 5.67
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol (2007) 2.71
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci (2008) 2.20
Environmental neurotoxin-induced progressive model of parkinsonism in rats. Ann Neurol (2010) 2.17
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct (2011) 1.94
Microglial activation and chronic neurodegeneration. Neurotherapeutics (2010) 1.87
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.86
Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect (2005) 1.80
T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol (2009) 1.78
Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci U S A (2009) 1.78
Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm (Vienna) (2010) 1.66
Minding the calcium store: Ryanodine receptor activation as a convergent mechanism of PCB toxicity. Pharmacol Ther (2009) 1.63
Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 1.61
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A (2004) 1.59
Multisystem Lewy body disease and the other parkinsonian disorders. Nat Genet (2015) 1.57
Viral parkinsonism. Biochim Biophys Acta (2008) 1.57
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
Animal models of Parkinson's disease progression. Acta Neuropathol (2008) 1.49
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation (2004) 1.43
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One (2008) 1.39
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci (2011) 1.38
A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med (2011) 1.36
Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res (2009) 1.35
Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34
Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation (2006) 1.32
The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31
Associations between indoor environmental factors and parental-reported autistic spectrum disorders in children 6-8 years of age. Neurotoxicology (2009) 1.28
CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation (2011) 1.27
Mitochondrial dynamics in Parkinson's disease. Exp Neurol (2009) 1.24
Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol (2008) 1.23
Role of oxidative stress in Parkinson's disease. Exp Neurobiol (2013) 1.23
MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci (2013) 1.21
Targeting neural precursors in the adult brain rescues injured dopamine neurons. Proc Natl Acad Sci U S A (2009) 1.21
Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol (2013) 1.20
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem (2010) 1.20
Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis. Surg Neurol Int (2011) 1.19
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One (2013) 1.12
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain (2010) 1.10
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol (2001) 1.09
Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J (2006) 1.09
Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci (2007) 1.07
Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease. Front Cell Neurosci (2014) 1.07
ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep (2012) 1.06
Complexity of dopamine metabolism. Cell Commun Signal (2013) 1.06
Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro (2013) 1.05
Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A (2012) 1.05
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 1.05
Cytotoxicity of paraquat in microglial cells: Involvement of PKCdelta- and ERK1/2-dependent NADPH oxidase. Brain Res (2007) 1.04
Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis (2010) 1.04
The role of early life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect (2005) 1.04
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol (2008) 1.03
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
The executioners sing a new song: killer caspases activate microglia. Cell Death Differ (2011) 1.02
MPTP mouse models of Parkinson's disease: an update. J Parkinsons Dis (2011) 1.02
Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease. PLoS One (2009) 1.02
IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis (2011) 1.00
The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci (2010) 1.00
Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology (2013) 1.00
Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis (2012) 1.00
Large animal models are critical for rationally advancing regenerative therapies. Regen Med (2006) 1.00
Bone marrow-derived mesenchymal stem cell therapy as a candidate disease-modifying strategy in Parkinson's disease and multiple system atrophy. J Clin Neurol (2009) 0.99
Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radic Biol Med (2008) 0.99
Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther (2008) 0.98
Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid Redox Signal (2011) 0.97
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol (2015) 0.97
Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol (2012) 0.96
Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One (2009) 0.95
Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci (2013) 0.95
Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/β-catenin dysregulation. J Neurosci (2013) 0.93
Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics (2014) 0.93
History of innate immunity in neurodegenerative disorders. Front Pharmacol (2011) 0.93
Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One (2012) 0.92
CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest (2009) 0.92
Environmental-genetic interactions in the pathogenesis of Parkinson's disease. Exp Neurobiol (2012) 0.92
Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis (2013) 0.91
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
MicroRNA-7 protects against 1-methyl-4-phenylpyridinium-induced cell death by targeting RelA. J Neurosci (2014) 0.89
Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease. Neurobiol Dis (2014) 0.89
Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm (Vienna) (2006) 0.89
Quercetin and sesamin protect dopaminergic cells from MPP+-induced neuroinflammation in a microglial (N9)-neuronal (PC12) coculture system. Oxid Med Cell Longev (2012) 0.89
Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord (2010) 0.89
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroinflammation (2010) 0.89
Evidence of inflammatory system involvement in Parkinson's disease. Biomed Res Int (2014) 0.89
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators Inflamm (2015) 0.89
Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis (2011) 0.88
Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One (2012) 0.88
A spirulina-enhanced diet provides neuroprotection in an α-synuclein model of Parkinson's disease. PLoS One (2012) 0.88
Inflammatory regulation of ATP binding cassette efflux transporter expression and function in microglia. J Pharmacol Exp Ther (2012) 0.87
Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology (2001) 6.42
Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities. N Engl J Med (1995) 4.19
The pathology of Parkinsonism: a comparison of degenerations in cerebral cortex and brainstem. Adv Neurol (1974) 3.14
Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc (1969) 2.01
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N Engl J Med (1992) 2.01
Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol (1976) 1.97
The hypothalamus in Parkinson disease. Ann Neurol (1978) 1.74
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res (1984) 1.71
Central corpectomy for cervical spondylotic myelopathy: a consecutive series with long-term follow-up evaluation. J Neurosurg (1991) 1.67
Nitroglycerin infusion during coronary-artery surgery. Anesthesiology (1976) 1.60
Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol (1986) 1.56
A homestyle delivery program in a university hospital. J Fam Pract (1979) 1.53
Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. Neurosci Lett (1986) 1.53
Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res (1989) 1.48
Alexia without agraphia associated with spleniogeniculate infarction. Neurology (1991) 1.45
Nicardipine, a new intravenous calcium antagonist: a review of its pharmacology, pharmacokinetics, and perioperative applications. J Cardiothorac Anesth (1989) 1.44
Value of coronary bypass surgery. Controversies in cardiology: Part I. Am J Cardiol (1978) 1.44
(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA (1988) 1.41
Subspecialty training in anesthesia: cardiac anesthesia faces a dilemma. J Cardiothorac Vasc Anesth (1992) 1.39
An unusual entrance wound associated with rimfire rifles. Am J Forensic Med Pathol (1991) 1.39
Peer review: another delicate balance. J Cardiothorac Anesth (1989) 1.39
Joseph disease: a multisystem degenerative disorder of the nervous system. Neurology (1982) 1.39
Hereditary form of parkinsonism--dementia. Ann Neurol (1998) 1.39
Duplicate publications. J Cardiothorac Vasc Anesth (1994) 1.38
Seven cases of cerebromedullospinal disconnection: the "locked-in" syndrome. Neurology (1971) 1.36
Hyperphagia, rage, and dementia accompanying a ventromedial hypothalamic neoplasm. Arch Neurol (1969) 1.33
1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett (1984) 1.24
Obstructive sleep apnea and near miss for SIDS: I. Report of an infant with sudden death. Pediatrics (1979) 1.22
Pargyline prevents MPTP-induced parkinsonism in primates. Science (1984) 1.22
Oxygenation and hemodynamic changes during one-lung ventilation: effects of CPAP10, PEEP10, and CPAP10/PEEP10. J Cardiothorac Anesth (1988) 1.20
The Lewy body in Parkinson's disease. Adv Neurol (1987) 1.19
Corpus callosotomy for intractable seizures in the pediatric age group. Arch Neurol (1991) 1.13
Peripheral neuropathy following amitriptyline overdose. Muscle Nerve (1985) 1.12
Postoperative analgesia for thoracotomy patients. Anesth Analg (1976) 1.11
Recurrent hemichorea following striatal lesions. Arch Neurol (1974) 1.09
Presenile dementia with Lewy bodies and neurofibrillary tangles. Arch Neurol (1978) 1.08
Status spongiosus in Jakob-Creutzfeldt disease. Electron microscopic study of a cortical biopsy. Brain (1970) 1.08
Clinical signs in diffuse cerebral dysfunction. J Neurol Neurosurg Psychiatry (1977) 1.06
Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res (1987) 1.01
Glial fibrillary acidic protein in hepatic encephalopathy. An immunohistochemical study. J Neuropathol Exp Neurol (1981) 1.01
Parkinson's disease and dementia with neuronal inclusions in the cerebral cortex: Lewy bodies or Pick bodies. J Neuropathol Exp Neurol (1988) 0.99
Reaction of the substantia nigra to massive basal ganglia infarction. Acta Neuropathol (1983) 0.99
Neuropathy in the hypereosinophilic syndrome. Muscle Nerve (1983) 0.98
Normal cerebrospinal fluid protein, increased intracranial pressure, and the Guillain-Barré syndrome. Ann Neurol (1977) 0.97
Hemodynamic interactions of verapamil and isoflurane. Anesthesiology (1983) 0.96
P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Pathol (1996) 0.96
Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration (1994) 0.96
The precordial electrocardiographic lead (V5) in patients who have coronary-artery disease. Anesthesiology (1976) 0.96
Criteria for operability and reduction of surgical mortality in patients with severe left ventricular ischemia and dysfunction. Ann Thorac Surg (1978) 0.95
Neurologic signs in senescence. Arch Neurol (1985) 0.94
Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology (1998) 0.94
"Hyperacute" subdural hematoma: CT mimic of recurrent episodes of bleeding in the setting of child abuse. J Forensic Sci (1996) 0.94
Alarming reactions to ketamine in patients taking thyroid medication--treatment with propranolol. Anesthesiology (1971) 0.93
Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases. J Neuropathol Exp Neurol (1985) 0.92
Spontaneous oral-facial dyskinesia: neuropathology of a case. Neurology (1983) 0.92
Clinical evaluation of a new fiberoptic catheter oximeter during cardiac surgery. Anesth Analg (1982) 0.91
Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. Am J Pathol (1994) 0.91
Experimental allergic neuritis in the Lewis rat. J Neuropathol Exp Neurol (1979) 0.91
Alexia without agraphia, hemianopia, or color-naming defect: a disconnection syndrome. Neurology (1977) 0.90
Validation of quantitative intraoperative transesophageal echocardiography. Anesthesiology (1986) 0.90
BK virus infection in AIDS. Am J Surg Pathol (2000) 0.90
Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res (1986) 0.89
Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol (1992) 0.89
Autologous blood transfusion during cardiac surgery. A re-evaluation of three methods. J Thorac Cardiovasc Surg (1977) 0.89
A rapid-onset, long-acting regional anesthetic technique. Anesthesiology (1974) 0.89
Prolonged focal epilepsy and hypoxemia as a cause of focal brain damage: a case study. Ann Neurol (1977) 0.89
Idiopathic orthostatic hypotension. Biochemical and pathologic observations in 2 cases. Eur Neurol (1975) 0.89
Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp Neurol (1998) 0.88
The nuchocephalic reflex. J Neurol Neurosurg Psychiatry (1975) 0.88
Vasodilator therapy during coronary artery surgery. Comparison of nitroglycerin and nitroprusside. J Thorac Cardiovasc Surg (1979) 0.87
Differential effects of septal and olfactory volleys on intracellular responses of hippocampal neurons in awake, sitting monkeys. J Neurophysiol (1970) 0.87
Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol (2000) 0.87
The renin--angiotensin--aldosterone system during cardiac surgery with morphine--nitrous oxide anesthesia. Anesthesiology (1975) 0.86
Sodium bicarbonate and systemic hemodynamics in volunteers anesthetized with halothane. Anesthesiology (1975) 0.86
Depigmentation in the nerve cells of the substantia nigra and locus ceruleus in Parkinsonism. Adv Neurol (1974) 0.86
Allescheria boydii infection of the brain. J Pathol (1972) 0.86
Alzheimer's disease: beta-amyloid precursor protein expression in plaques varies among cytoarchitectonic areas of the medial temporal lobe. Neurosci Lett (1991) 0.86
Early diagnosis of myocardial ischemia using the pulmonary arterial catheter. Anesth Analg (1981) 0.85
Story processing in right-hemisphere brain-damaged patients. Brain Lang (1992) 0.85
"Encephalomyeloneuritis" in the absence of cancer. Neurology (1975) 0.85
A comparison of hemodynamic indices derived by invasive monitoring and two-dimensional echocardiography. Anesthesiology (1987) 0.85
Shivering following cardiac surgery: hemodynamic changes and reversal. J Cardiothorac Anesth (1987) 0.85
Amyotrophic lateral sclerosis of the Guam type in a U.S. veteran. Neurology (1973) 0.84
Vasodilator therapy after cardiac surgery: a review of the efficacy and toxicity of nitroglycerin and nitroprusside. Can Anaesth Soc J (1980) 0.84
Behavioral and EEG asymmetry following unilateral lesions of the forebrain and midbrain in cats. Electroencephalogr Clin Neurophysiol (1971) 0.84
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology (2001) 0.84
Agenesis of the corpus callosum with hypothermia. Arch Neurol (1975) 0.84
Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease. Am J Pathol (1996) 0.84
Results of coronary revascularization in patients with recent myocardial infarction. J Thorac Cardiovasc Surg (1978) 0.83
Chronic neuropathy presenting as a floppy infant with respiratory distress. Pediatrics (1979) 0.83
Genetic control of susceptibility to experimental allergic neuritis and the immune response to P2 protein. Neurology (1981) 0.83
Synaptic morphology in the human locus ceruleus. Acta Neuropathol (1981) 0.82
Neuroaxonal dystrophy (Seitelberger's disease) with late onset, protracted course and myoclonic epilepsy. J Neurol Sci (1978) 0.82
Treatment response in malignant optic glioma of adulthood. Neurology (1988) 0.82
Pure alexia: clinical-pathologic evidence for a lateralized visual language association cortex. Clin Neuropathol (1998) 0.82
Measurement of GFAP in hepatic encephalopathy by ELISA and transblots. J Neuropathol Exp Neurol (1985) 0.82
The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res (1990) 0.81
Paraneoplastic encephalomyelitis. Acta Neurol Scand (1972) 0.81
Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert. Am J Pathol (1992) 0.81
[3H]thymidine labeling of astrocytes in experimental allergic encephalomyelitis. J Neuroimmunol (1987) 0.81